9.Fogel R.B., Malhotra A., Dalagiorgou G., Robinson M.K., Jakab M., Kikinis R., Pittman S.D., White D.P. Anatomic and physiologic predictors of apnea severity in morbidly obese subjects. Sleep. Mar. № 15, 2003; 26 (2): 150—5.
10.Girault C., Muir J., Mihaltan F. Effect of repeated administration of zolpidem on sleep, diurnal and nocturnal respiratory function, vigilance, and physical per formance in patients with COPD. Chest. 1996; 110: 1203—1211.
11.Guilleminault C., van den Hoed J., Mitler M. Clinical overview of the sleep apnea syndromes. in Guilleminault C, Dement W.C. Sleep Apnea Syndromes. New York. Alan R Liss, 1978; 1—12.
12.Heijdra Y., Dekhuijzen P., Hypoxia, almitrine and peripheral neuropathy. Thorax. 1989; 44: 247—250.
13.Indications and standards for use of nasal continuous positive airway pres sure (CPAP) in sleep apnea syndromes. Am J Respir Care Med. 1994; 150: 1738— 174.
14.Kumano Go T., Mikami A., Suganuma N., Adachi H., Watanabe T., Shigedo Y., Sugita Y., Takeda M. Three components of obstructive sleep apnea/hypopnea syndrome. Psychiatry Clin. Neurosci. Apr. 2003; 57 (2): 197—203.
15.Lemes L.N., Melo P.L. Long term effects of almitrine bismesylate on oxygenation during wakefulness and sleep in chronic obstructive pulmonary disease. Am I Med. 1988; 84: 436—443.
16.Mar J., Rueda J.R., Duran Cantolla J., Schechter C., Chilcott J. The cost effec tiveness of CPAP treatment in patients with moderate to severe obstructive sleep apnoea. Eur Respir J. Mar. 2003; 21 (3): 515—22.
17.Massie C.A., Hart R.W. Clinical outcomes related to interface type in patients with obstructive sleep apnea/hypopnea syn drome who are using continuous positive
airway pressure. Chest. Apr. 2003; 123 (4): 1112—8.
18.McMahon J.P., Foresman B.H., Chisholm R.C. The influence of CPAP on the neurobehavioral per formance of patients with obstruc tive sleep apnea hypopnea syndrome: a systematic review. WMJ. 2003; 102 (1): 36—43.
19.Meyer T.K., Woodson T. Surgical man agement of snoring and obstructive sleep apnea. WMJ. 2003; 102 (1): 28—31.
20.Nakano H., Ikeda T., Hayashi M., Ohshima E., Onizuka A. Effects of body position on snoring in apneic and nonap neic snorers. Sleep. Mar. № 15, 2003; 26 (2): 169—72.
21.Pearce S., Saunders P. Obstructive sleep apnoea can directly cause death. Thorax. Apr. 2003; 58 (4): 369.
22.Phillips B. Definitions of the metabolic syndrome. JAMA. Mar. № 12, 2003; 289 (10): 1241.
23.Rapoport D. Treatment of sleep apnea syndrome. Mt Sinai J Med. 1994; 61: 123—130.
24.Riordan J., Sillett R., Mc.Nicollas M. A controlled trial of Doxapram in acute res piratory failure. Br J Dis Chest. 1975; 69: 57—62.
25.Said B., Strome M. Long term results of radiofrequency volumetric tissue reduc tion of the palate for snoring. Ann Otol. Rhinol. Laryngol. Mar. 2003; 112 (3): 276—9.
26.Sato K. Oral appliances used in treating obstructive sleep apnea syndrome — par ticipation by otolaryngologists. Nippon Jibiinkoka Gakkai Kaiho. Feb. 2003; 106 (2): 150—5.
27.Shneerson J. Managing sleep disorders. Practitioner. Mar. 2003; 247 (1644): 231—5.
28.Siafakas N., Vermeire P., Pride N. Changes in day and in night time oxy genation with protriptyline in patients